Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in
patients with chronic myelogenous leukemia in chronic phase who are in relapse after stem
cell transplantation.